Programmed Cell Death 1 Ligand 2 Protéines

Greisen, Kragstrup, Thomsen, Hansen, Krishnamurthy, Hørslev-Petersen, Hetland, Stengaard-Pedersen, Østergaard, Ørnbjerg, Junker, Sharpe, Freeman, Annamalai, Hvid, Moestrup, Hauge, Catrina, Deleuran: "Programmed death ligand 2 - A link between inflammation and bone loss in rheumatoid arthritis." dans: Journal of translational autoimmunity, Vol. 3, pp. 100028, (2020) (PubMed).

Tocheva, Lerrer, Mor: "In Vitro Assays to Study PD-1 Biology in Human T Cells." dans: Current protocols in immunology, Vol. 130, Issue 1, pp. e103, (2020) (PubMed).

Tocheva, Peled, Strazza, Adam, Lerrer, Nayak, Azoulay-Alfaguter, Foster, Philips, Neel, Ueberheide, Mor: "Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions." dans: The Journal of biological chemistry, Vol. 295, Issue 52, pp. 18036-18050, (2020) (PubMed).

Zhao, Lee, Lin, Gassen, Xu, Huang, Xiao, Bonorino, Lu, Bui, Hui: "PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways." dans: Immunity, Vol. 51, Issue 6, pp. 1059-1073.e9, (2019) (PubMed).

Fromm, de Silva, Johannes, Patel, Hornblower, Schreiber: "Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy." dans: Journal for immunotherapy of cancer, Vol. 6, Issue 1, pp. 149, (2018) (PubMed).

Arlauckas, Garris, Kohler, Kitaoka, Cuccarese, Yang, Miller, Carlson, Freeman, Anthony, Weissleder, Pittet: "In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy." dans: Science translational medicine, Vol. 9, Issue 389, (2018) (PubMed).